Case Name |
Date Filed |
Judge |
Drug |
Patent No(s). |
Pharmacyclics LLC v. Hetero USA Inc., 19-0014 (D. Del.) |
Jan. 4, 2019 |
Hon. Colm F. Connolly |
Imbruvica® (ibrutinib capsules) |
10,106,548 |
Valeant Pharms. North America LLC v. Strides Pharma Inc., 19-0133 (D.N.J.) |
Jan. 4, 2019 |
Hon. Peter G. Sheridan |
Jublia® (efinaconazole topical solution) |
10,105,444 |
Celgene Corp. v. Aurobindo Pharma Ltd., 19-0143 (D.N.J.) |
Jan. 4, 2019 |
Hon. Esther Salas |
Pomalyst® (pomalidomide capsules) |
9,993,467 |
Arbor Pharms., LLC v. Teva Pharms. USA, Inc., 19-0053 (D. Del.) |
Jan. 9, 2019 |
Hon. Colm F. Connolly |
Sklice® (ivermectin lotion) |
8,791,153
8,927,595 |
Bristol-Myers Squibb Co. v. Unichem Labs., Ltd., 19-0055 (D. Del.) |
Jan. 9, 2019 |
Hon. Leonard P. Stark |
Eliquis® (apixaban tablets) |
6,967,208 |
Sun Pharm. Indus. Ltd. v. Novartis Pharms. Corp., 19-0276 (D.N.J.) |
Jan. 9, 2019 |
Hon. Susan D. Wigenton |
Jadenu® (deferasirox tablets) |
9,283,209 |
Moderna Therapeutics, Inc. v. Arbutus Biopharma Corp., IPR2019-00554 (PTAB) |
Jan. 9, 2019 |
N/A |
Onpattro® (patisiran sodium for injection) |
8,058,069 |
Onyx Therapeutics, Inc. v. Breckenridge Pharm., Inc., 19-0071 (D. Del.) |
Jan. 11, 2019 |
Hon. Leonard P. Stark |
Kyprolis® (carfilzomib for injection) |
7,417,042
7,737,112
8,207,125 |
Genentech, Inc. v. Laurus Labs Ltd., 19-0078 (D. Del.) |
Jan. 14, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone capsules) |
7,566,729
7,635,707
7,767,700
7,816,383
7,910,610
8,013,002
8,084,475
8,318,780
8,383,150
8,420,674
8,592,462
8,609,701
8,648,098
8,754,109
8,778,947
7,696,236
7,767,225
7,988,994
8,753,679 |
Gilead Sciences, Inc. v. Zydus Pharms. (USA) Inc., 19-0529 (D.N.J.) |
Jan. 15, 2019 |
Hon. Brian R. Martinotti |
Truvada® (emtricitabine / tenofovir disoproxil fumarate tablets) |
6,642,245
6,703,396
8,592,397
8,716,264
9,457,036
9,744,181 |
Genentech, Inc. v. Aurobindo Pharma Ltd., 19-0103 (D. Del.) |
Jan. 17, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone capsules) |
7,566,729
7,635,707
7,767,700
7,816,383
7,910,610
8,013,002
8,084,475
8,318,780
8,383,150
8,420,674
8,592,462
8,609,701
8,648,098
8,754,109
8,778,947
7,696,236
7,767,225
7,988,994
8,753,679 |
Genentech, Inc. v. Laurus Labs Ltd., 19-0104 (D. Del.) |
Jan. 17, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone tablets) |
7,566,729
7,635,707
7,767,700
7,816,383
7,910,610
8,013,002
8,084,475
8,318,780
8,383,150
8,420,674
8,592,462
8,609,701
8,648,098
8,754,109
8,778,947 |
Genentech, Inc. v. Aurobindo Pharma Ltd., 19-0105 (D. Del.) |
Jan. 17, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone tablets) |
7,566,729
7,635,707
7,767,700
7,816,383
7,910,610
8,013,002
8,084,475
8,318,780
8,383,150
8,420,674
8,592,462
8,609,701
8,648,098
8,754,109
8,778,947
9,561,217 |
Beloteca, Inc. v. Apicore US LLC, 19-0360 (N.D. Ill.) |
Jan. 17, 2019 |
Hon. John J. Tharp, Jr. |
Lymphazurin® (isosulfan blue for injection) |
7,662,992
8,969,616
9,353,050 |
Genentech, Inc. v. Lupin Ltd., 19-0109 (D. Del.) |
Jan. 18, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone capsules) |
7,566,729
7,635,707
7,767,700
7,816,383
7,910,610
8,013,002
8,084,475
8,318,780
8,383,150
8,420,674
8,592,462
8,609,701
8,648,098
8,754,109
8,778,947
7,696,236
7,767,225
7,988,994
8,753,679 |
Genentech, Inc. v. Lupin Ltd., 19-0110 (D. Del.) |
Jan. 18, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone tablets) |
7,566,729
7,635,707
7,767,700
7,816,383
7,910,610
8,013,002
8,084,475
8,318,780
8,383,150
8,420,674
8,592,462
8,609,701
8,648,098
8,754,109
8,778,947 |
Genentech, Inc. v. Micro Labs Ltd., 19-0111 (D. Del.) |
Jan. 18, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone tablets) |
7,566,729
7,635,707
7,767,700
7,816,383
7,910,610
8,013,002
8,084,475
8,318,780
8,383,150
8,420,674
8,592,462
8,609,701
8,648,098
8,754,109
8,778,947 |
Genentech, Inc. v. Apotex Inc., 19-0120 (D. Del.) |
Jan. 22, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone capsules) |
7,566,729
7,635,707
7,767,700
7,816,383
7,910,610
8,013,002
8,084,475
8,318,780
8,383,150
8,420,674
8,592,462
8,609,701
8,648,098
8,754,109
8,778,947
7,696,236
7,767,225
7,988,994
8,753,679 |
Genentech, Inc. v. Apotex Inc., 19-0123 (D. Del.) |
Jan. 22, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone tablets) |
7,566,729
7,635,707
7,767,700
7,816,383
7,910,610
8,013,002
8,084,475
8,318,780
8,383,150
8,420,674
8,592,462
8,609,701
8,648,098
8,754,109
8,778,947
9,561,217 |
Par Pharm., Inc. v. Pfizer Inc., 19-0615 (S.D.N.Y.) |
Jan. 22, 2019 |
Hon. William H. Pauley, III |
Chantix® (varenicline tartrate tablets) |
6,890,927
7,265,119 |
Genentech, Inc. v. Shilpa Medicare Ltd., 19-0130 (D. Del.) |
Jan. 23, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone tablets) |
8,383,150
8,778,947 |
Genentech, Inc. v. SciGen Pharms. Inc., 19-0131 (D. Del.) |
Jan. 23, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone tablets) |
8,383,150
9,561,217 |
Genentech, Inc. v. SciGen Pharms. Inc., 19-0132 (D. Del.) |
Jan. 23, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone capsules) |
8,383,150
8,420,674
7,767,225
7,988,994
8,753,679 |
Valeant Pharms. North America LLC v. Cipla Ltd., 19-0988 (D.N.J.) |
Jan. 23, 2019 |
Hon. Peter G. Sheridan |
Jublia® (efinaconazole topical solution) |
10,105,444 |
Valeant Pharms. North America LLC v. Teva Pharms. USA, Inc., 19-0990 (D.N.J.) |
Jan. 23, 2019 |
Hon. Peter G. Sheridan |
Jublia® (efinaconazole topical solution) |
10,105,444 |
Genentech, Inc. v. Teva Pharms. USA, Inc., 19-0136 (D. Del.) |
Jan. 24, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone tablets) |
7,566,729
7,635,707
7,767,700
7,816,383
7,910,610
8,013,002
8,084,475
8,318,780
8,383,150
8,420,674
8,592,462
8,609,701
8,648,098
8,754,109
8,778,947 |
Taro Pharm. Indus. Ltd. v. Novitium Pharma, LLC, 19-1028 (D.N.J.) |
Jan. 24, 2019 |
Hon. Freda L. Wolfson |
Ovide® (malathion lotion) |
7,560,445
7,977,324 |
Japan Tobacco Inc. v. Mylan Pharms. Inc., 19-0012 (N.D.W.V.) |
Jan. 24, 2019 |
Hon. Irene M. Keeley |
Stribild® (elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil fumarate tablets) |
8,633,219 |
Genentech, Inc. v. Accord Healthcare, Inc., 19-0141 (D. Del.) |
Jan. 25, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone capsules) |
7,566,729
7,635,707
7,767,700
7,816,383
7,910,610
8,013,002
8,084,475
8,318,780
8,383,150
8,420,674
8,592,462
8,609,701
8,648,098
8,754,109
8,778,947
7,696,236
7,767,225
7,988,994
8,753,679 |
Genentech, Inc. v. Accord Healthcare, Inc., 19-0142 (D. Del.) |
Jan. 25, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone tablets) |
7,566,729
7,635,707
7,767,700
7,816,383
7,910,610
8,013,002
8,084,475
8,318,780
8,383,150
8,420,674
8,592,462
8,609,701
8,648,098
8,754,109
8,778,947 |
Pharmacyclics LLC v. Zydus Worldwide DMCC, 19-0143 (D. Del.) |
Jan. 25, 2019 |
Hon. Colm F. Connolly |
Imbruvica® (ibrutinib capsules) |
7,514,444
8,008,309
8,697,711
8,735,403
8,957,079
9,181,257
8,754,091
8,497,277
8,952,015
8,476,284
8,754,090
9,296,753
9,725,455
10,125,140
10,106,548 |
Genentech, Inc. v. Macleods Pharms. Ltd., 19-0154 (D. Del.) |
Jan. 28, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone capsules) |
7,566,729
7,635,707
7,767,700
7,816,383
7,910,610
8,013,002
8,084,475
8,318,780
8,383,150
8,420,674
8,592,462
8,609,701
8,648,098
8,754,109
8,778,947
7,696,236
7,767,225
7,988,994
8,753,679 |
Genentech, Inc. v. Granules Pharms., Inc., 19-0164 (D. Del.) |
Jan. 28, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone tablets) |
8,383,150
8,420,674
8,778,947 |
Genentech, Inc. v. Alembic Pharms., Ltd., 19-0177 (D. Del.) |
Jan. 29, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone tablets) |
7,566,729
7,635,707
7,767,700
7,816,383
7,910,610
8,013,002
8,084,475
8,318,780
8,383,150
8,420,674
8,592,462
8,609,701
8,648,098
8,754,109
8,778,947 |
Genentech, Inc. v. Hetero Labs Ltd., 19-0178 (D. Del.) |
Jan. 29, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone tablets) |
7,566,729
7,635,707
7,767,700
7,816,383
7,910,610
8,013,002
8,084,475
8,318,780
8,383,150
8,420,674
8,592,462
8,609,701
8,648,098
8,754,109
8,778,947 |
Genentech, Inc. v. Amneal Pharms. LLC, 19-0190 (D. Del.) |
Jan. 30, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone tablets) |
7,566,729
7,635,707
7,767,700
7,816,383
7,910,610
8,013,002
8,084,475
8,318,780
8,383,150
8,420,674
8,592,462
8,609,701
8,648,098
8,754,109
8,778,947 |
Genentech, Inc. v. Amneal Pharms. LLC, 19-0195 (D. Del.) |
Jan. 30, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone capsules) |
7,566,729
7,635,707
7,767,700
7,816,383
7,910,610
8,013,002
8,084,475
8,318,780
8,383,150
8,420,674
8,592,462
8,609,701
8,648,098
8,754,109
8,778,947
7,696,236
7,767,225
7,988,994
8,753,679 |
Galephar Pharm. Research, Inc. v. Upsher-Smith Labs., LLC, 19-2546 (D.N.J.) |
Jan. 30, 2019 |
Hon. Madeline Cox Arleo |
Absorica® (isotretinoin capsules) |
7,435,427
8,367,102
8,952,064
9,078,925
9,089,534 |
Genentech, Inc. v. Sandoz, Inc., 19-0202 (D. Del.) |
Jan. 31, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone tablets) |
7,566,729
7,635,707
7,767,700
7,816,383
7,910,610
8,013,002
8,084,475
8,318,780
8,383,150
8,420,674
8,592,462
8,609,701
8,648,098
8,754,109
8,778,947
9,561,217 |
Genentech, Inc. v. Sandoz, Inc., 19-0203 (D. Del.) |
Jan. 31, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone capsules) |
7,566,729
7,635,707
7,767,700
7,816,383
7,910,610
8,013,002
8,084,475
8,318,780
8,383,150
8,420,674
8,592,462
8,609,701
8,648,098
8,754,109
8,778,947
7,696,236
7,767,225
7,988,994
8,753,679 |
Genentech, Inc. v. MSN Labs. Private Ltd., 19-0205 (D. Del.) |
Jan. 31, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone tablets) |
8,383,150
8,778,947 |
Biogen Int’l GmbH v. Hetero USA Inc., 19-0211 (D. Del.) |
Jan. 31, 2019 |
Hon. Leonard P. Stark |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
7,619,001 |
Genentech, Inc. v. Cipla Ltd., 19-0219 (D. Del.) |
Feb. 1, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone tablets) |
7,566,729
7,635,707
7,767,700
7,816,383
7,910,610
8,013,002
8,084,475
8,318,780
8,383,150
8,420,674
8,592,462
8,609,701
8,648,098
8,754,109
8,778,947 |
Keryx Biopharmaceuticals, Inc. v. Chemo Research S.L., 19-0220 (D. Del.) |
Feb. 1, 2019 |
Hon. Leonard P. Stark |
Auryxia® (ferric citrate tablets) |
5,753,706
7,767,851
8,093,423
8,299,298
8,338,642
8,609,896
8,754,257
8,754,258
8,846,976
8,901,349
9,050,316
9,328,133
9,387,191
9,757,416 |
Leo Pharma A/S v. Taro Pharms. U.S.A., 19-0221 (D. Del.) |
Feb. 1, 2019 |
Hon. Colm F. Connolly |
Finacea® (azelaic acid foam) |
7,700,076
8,435,498
8,722,021
8,900,554
9,211,259
9,265,725
10,117,812 |
Genentech, Inc. v. Aizant Drug Research Solutions Pvt. Ltd., 19-0223 (D. Del.) |
Feb. 1, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone tablets) |
7,566,729
7,635,707
7,767,700
7,816,383
7,910,610
8,013,002
8,084,475
8,318,780
8,383,150
8,420,674
8,592,462
8,609,701
8,648,098
8,754,109
8,778,947 |
Par Pharm., Inc. v. Merck Sharp & Dohme Corp., 19-4432 (D.N.J.) |
Feb. 1, 2019 |
Hon. Madeline Cox Arleo |
Janumet® XR (sitagliptin phosphate / metformin HCl extended-release tablets) |
7,326,708 |
Leo Pharma A/S v. Taro Pharms. U.S.A., 19-1051 (S.D.N.Y.) |
Feb. 4, 2019 |
Hon. Colleen McMahon |
Finacea® (azelaic acid foam) |
7,700,076
8,435,498
8,722,021
8,900,554
9,211,259
9,265,725
10,117,812 |
Genzyme Corp. v. Zenara Pharma Private Ltd., 19-0264 (D. Del.) |
Feb. 7, 2019 |
Hon. Colm F. Connolly |
Cerdelga® (eliglustat capsules) |
6,916,802
7,196,205
7,253,185
7,615,573 |
Corcept Therapeutics Inc. v. Teva Pharms. USA, Inc., 19-5066 (D.N.J.) |
Feb. 8, 2019 |
Hon. Susan D. Wigenton |
Korlym® (mifepristone tablets) |
10,166,242
10,166,243
10,195,214 |
Genzyme Corp. v. Zenara Pharma Private Ltd., 19-5160 (D.N.J.) |
Feb. 8, 2019 |
Hon. Brian R. Martinotti |
Cerdelga® (eliglustat capsules) |
6,916,802
7,196,205
7,253,185
7,615,573 |
Valeant Pharms. North America LLC v. Zydus Pharms. (USA) Inc., 19-5162 (D.N.J.) |
Feb. 8, 2019 |
Hon. Peter G. Sheridan |
Jublia® (efinaconazole topical solution) |
10,105,444 |
Biogen Int’l GmbH v. Accord Healthcare Inc., 19-0303 (D. Del.) |
Feb. 12, 2019 |
Hon. Leonard P. Stark |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
7,619,001 |
Meda Pharms. Inc. v. Aurobindo Pharma Ltd., 19-5501 (D.N.J.) |
Feb. 12, 2019 |
Hon. Brian R. Martinotti |
Astepro® (azelastine HCl nasal spray) |
8,071,073
8,518,919
9,919,050 |
Merck Sharp & Dohme Corp. v. Alvogen Pine Brook LLC, 19-0310 (D. Del.) |
Feb. 13, 2019 |
Hon. Richard G. Andrews |
Janumet® XR (sitagliptin phosphate / metformin HCl extended-release tablets) |
7,326,708 |
Merck Sharp & Dohme Corp. v. Anchen Pharms., Inc., 19-0311 (D. Del.) |
Feb. 13, 2019 |
Hon. Richard G. Andrews |
Janumet® XR (sitagliptin phosphate / metformin HCl extended-release tablets) |
7,326,708 |
Merck Sharp & Dohme Corp. v. Sandoz Inc., 19-0312 (D. Del.) |
Feb. 13, 2019 |
Hon. Richard G. Andrews |
Janumet® XR (sitagliptin phosphate / metformin HCl extended-release tablets)
Januvia® (sitagliptin phosphate)
|
7,326,708 |
Merck Sharp & Dohme Corp. v. Apotex Inc., 19-0313 (D. Del.) |
Feb. 13, 2019 |
Hon. Richard G. Andrews |
Janumet® XR (sitagliptin phosphate / metformin HCl extended-release tablets)
Januvia® (sitagliptin phosphate)
Janumet® (sitagliptin phosphate / metformin HCl) |
7,326,708 |
Merck Sharp & Dohme Corp. v. Zydus Pharms. (USA) Inc., 19-0314 (D. Del.) |
Feb. 13, 2019 |
Hon. Richard G. Andrews |
Janumet® XR (sitagliptin phosphate / metformin HCl extended-release tablets)
Januvia® (sitagliptin phosphate)
Janumet® (sitagliptin phosphate / metformin HCl) |
7,326,708 |
Merck Sharp & Dohme Corp. v. Mylan Pharms. Inc., 19-0315 (D. Del.) |
Feb. 13, 2019 |
Hon. Richard G. Andrews |
Januvia® (sitagliptin phosphate) |
7,326,708
8,414,921 |
Merck Sharp & Dohme Corp. v. Macleods Pharms. Ltd., 19-0316 (D. Del.) |
Feb. 13, 2019 |
Hon. Richard G. Andrews |
Januvia® (sitagliptin phosphate)
Janumet® (sitagliptin phosphate / metformin HCl) |
7,326,708 |
Merck Sharp & Dohme Corp. v. Watson Labs., Inc., 19-0317 (D. Del.) |
Feb. 13, 2019 |
Hon. Richard G. Andrews |
Januvia® (sitagliptin phosphate) |
7,326,708
8,414,921 |
Merck Sharp & Dohme Corp. v. Teva Pharms. USA, Inc., 19-0318 (D. Del.) |
Feb. 13, 2019 |
Hon. Richard G. Andrews |
Janumet® XR (sitagliptin phosphate / metformin HCl extended-release tablets)
Januvia® (sitagliptin phosphate)
Janumet® (sitagliptin phosphate / metformin HCl)
Juvisync® (simvastatin/ sitagliptin phosphate) |
7,326,708 |
Merck Sharp & Dohme Corp. v. Sun Pharma Global FZE, 19-0319 (D. Del.) |
Feb. 13, 2019 |
Hon. Richard G. Andrews |
Janumet® XR (sitagliptin phosphate / metformin HCl extended-release tablets)
Januvia® (sitagliptin phosphate)
Janumet® (sitagliptin phosphate / metformin HCl) |
7,326,708
8,414,921 |
Merck Sharp & Dohme Corp. v. Torrent Pharms. Ltd., 19-0320 (D. Del.) |
Feb. 13, 2019 |
Hon. Richard G. Andrews |
Januvia® (sitagliptin phosphate) |
7,326,708 |
Merck Sharp & Dohme Corp. v. Wockhardt Bio AG, 19-0321 (D. Del.) |
Feb. 13, 2019 |
Hon. Richard G. Andrews |
Januvia® (sitagliptin phosphate)
Janumet® (sitagliptin phosphate / metformin HCl) |
7,326,708 |
Genentech, Inc. v. Torrent Pharms. Ltd., 19-0324 (D. Del.) |
Feb. 14, 2019 |
Hon. Richard G. Andrews |
Esbriet® (pirfenidone tablets) |
8,383,150
8,778,947 |
Celgene Corp. v. Hetero Labs Ltd., 19-5797 (D.N.J.) |
Feb. 14, 2019 |
Hon. Esther Salas |
Pomalyst® (pomalidomide capsules) |
10,093,647
10,093,648
10,093,649 |
Celgene Corp. v. Aurobindo Pharma Ltd., 19-5799 (D.N.J.) |
Feb. 14, 2019 |
Hon. Esther Salas |
Pomalyst® (pomalidomide capsules) |
10,093,647
10,093,648
10,093,649 |
Celgene Corp. v. Mylan Pharms. Inc., 19-5802 (D.N.J.) |
Feb. 14, 2019 |
Hon. Esther Salas |
Pomalyst® (pomalidomide capsules) |
10,093,647
10,093,648
10,093,649 |
Celgene Corp. v. Breckenridge Pharm., Inc., 19-5804 (D.N.J.) |
Feb. 14, 2019 |
Hon. Esther Salas |
Pomalyst® (pomalidomide capsules) |
10,093,647
10,093,648
10,093,649 |
Celgene Corp. v. Apotex Inc., 19-5806 (D.N.J.) |
Feb. 14, 2019 |
Hon. Esther Salas |
Pomalyst® (pomalidomide capsules) |
10,093,647
10,093,648
10,093,649 |
Valeant Pharms. North America LLC v. Apotex Inc., 19-5939 (D.N.J.) |
Feb. 15, 2019 |
Hon. Peter G. Sheridan |
Jublia® (efinaconazole topical solution) |
10,105,444 |
Biogen Int’l GmbH v. Zydus Pharms. (USA) Inc., 19-5987 (D.N.J.) |
Feb. 15, 2019 |
Hon. Brian R. Martinotti |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
7,619,001 |
Merck Sharp & Dohme Corp. v. Lupin Ltd., 19-0347 (D. Del.) |
Feb. 19, 2019 |
Hon. Richard G. Andrews |
Janumet® (sitagliptin phosphate / metformin HCl) |
7,326,708 |
Galderma Labs. L.P. v. Teva Pharms. USA, Inc., 19-0351 (D. Del.) |
Feb. 19, 2019 |
Hon. Richard G. Andrews |
Soolantra® (ivermectin cream) |
10,206,939 |
Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000685 (PTAB) |
Feb. 19, 2019 |
N/A |
Narcan® (naloxone HCl nasal spray) |
9,211,253 |
Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000686 (PTAB) |
Feb. 19, 2019 |
N/A |
Narcan® (naloxone HCl nasal spray) |
9,211,253 |
Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000687 (PTAB) |
Feb. 19, 2019 |
N/A |
Narcan® (naloxone HCl nasal spray) |
9,211,253 |
Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000688 (PTAB) |
Feb. 19, 2019 |
N/A |
Narcan® (naloxone HCl nasal spray) |
9,468,747 |
Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000689 (PTAB) |
Feb. 19, 2019 |
N/A |
Narcan® (naloxone HCl nasal spray) |
9,468,747 |
Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000690 (PTAB) |
Feb. 19, 2019 |
N/A |
Narcan® (naloxone HCl nasal spray) |
9,468,747 |
Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000691 (PTAB) |
Feb. 19, 2019 |
N/A |
Narcan® (naloxone HCl nasal spray) |
9,561,177 |
Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000692 (PTAB) |
Feb. 19, 2019 |
N/A |
Narcan® (naloxone HCl nasal spray) |
9,561,177 |
Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000693 (PTAB) |
Feb. 19, 2019 |
N/A |
Narcan® (naloxone HCl nasal spray) |
9,561,177 |
Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000694 (PTAB) |
Feb. 19, 2019 |
N/A |
Narcan® (naloxone HCl nasal spray) |
9,629,965 |
Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000695 (PTAB) |
Feb. 19, 2019 |
N/A |
Narcan® (naloxone HCl nasal spray) |
9,629,965 |
Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000696 (PTAB) |
Feb. 19, 2019 |
N/A |
Narcan® (naloxone HCl nasal spray) |
9,629,965 |
Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000697 (PTAB) |
Feb. 19, 2019 |
N/A |
Narcan® (naloxone HCl nasal spray) |
9,775,838 |
Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000698 (PTAB) |
Feb. 19, 2019 |
N/A |
Narcan® (naloxone HCl nasal spray) |
9,775,838 |
Nalox-1 Pharms., LLC v. Opiant Pharms., Inc., IPR2019-000699 (PTAB) |
Feb. 19, 2019 |
N/A |
Narcan® (naloxone HCl nasal spray) |
9,775,838 |
Celgene Corp. v. Apotex Inc., 19-6999 (D.N.J.) |
Feb. 26, 2019 |
Hon. Susan D. Wigenton |
Revlimid® (lenalidomide capsules) |
7,189,740
8,404,717
9,056,120 |
Mitsubishi Tanabe Pharma Corp. v. Lupin Ltd., 19-7165 (D.N.J.) |
Feb. 27, 2019 |
Hon. Peter G. Sheridan |
Invokamet XR® (canagliflozin / metformin HCl extended-release tablets) |
7,943,582
8,513,202 |
Valeant Pharms. North America LLC v. Macleods Pharms. Ltd., 19-7296 (D.N.J.) |
Feb. 28, 2019 |
Hon. Peter G. Sheridan |
Jublia® (efinaconazole topical solution) |
10,105,444 |
Pharmacyclics LLC v. Alvogen Pine Brook LLC, 19-0434 (D. Del.) |
Mar. 1, 2019 |
Hon. Colm F. Connolly |
Imbruvica® (ibrutinib capsules) |
7,514,444
8,008,309
8,476,284
8,497,277
8,697,711
8,735,403
8,754,090
8,754,091
8,952,015
8,957,079
9,181,257
9,296,753
9,655,857
9,725,455
10,010,507
10,106,548
10,125,140 |
Endo Pharms. Inc. v. Perrigo UK Finco Ltd., 19-0437 (D. Del.) |
Mar. 1, 2019 |
Hon. Maryellen Noreika |
Nascobal® (cyanocobalamin nasal spray) |
7,229,636
7,404,489
7,879,349
8,003,353
8,940,714
9,415,007 |
Cipla Ltd. v. AstraZeneca AB, 19-0438 (D. Del.) |
Mar. 1, 2019 |
Hon. Maryellen Noreika |
Nexium® (esomeprazole magnesium delayed-release oral suspension) |
6,428,810 |
Galderma Labs., L.P. v. Amneal Pharms. LLC, 19-0440 (D. Del.) |
Mar. 1, 2019 |
Hon. Leonard P. Stark |
Oracea® (doxycycline capsules) |
10,058,564 |
Biodelivery Sciences Int’l, Inc. v. Chemo Research, S.L., 19-0444 (D. Del.) |
Mar. 1, 2019 |
Hon. Colm F. Connolly |
Belbuca® (buprenorphine buccal film) |
8,147,866
9,655,843
9,901,539 |
Sun Pharm. Indus. Ltd. v. Vistapharm, Inc., 19-7536 (D.N.J.) |
Mar. 1, 2019 |
Hon. Stanley R. Chesler |
Riomet® (metformin HCl oral solution) |
6,890,957 |
Apicore US LLC v. Beloteca, Inc., 19-0077 (E.D. Tex.) |
Mar. 4, 2019 |
Hon. Rodney Gilstrap |
Isosulfan blue for injection |
8,969,616
9,353,050 |
Sawai USA, Inc. v. Biogen MA, Inc., IPR2019-00789 (PTAB) |
Mar. 4, 2019 |
N/A |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
8,399,514 |
Millennium Pharms., Inc. v. Aurobindo Pharma USA Inc., 19-0471 (D. Del.) |
Mar. 6, 2019 |
Hon. Colm F. Connolly |
Velcade® (bortezomib for injection) |
6,713,446
6,958,319 |
UCB, Inc. v. Actavis Labs. UT, Inc., 19-0474 (D. Del.) |
Mar. 6, 2019 |
Hon. Leonard P. Stark |
Neupro® (rotigotine transdermal system) |
10,130,589 |
Valeant Pharms. North America LLC v. Slayback Pharma, LLC, 19-8218 (D.N.J.) |
Mar. 8, 2019 |
Hon. Peter G. Sheridan |
Jublia® (efinaconazole topical solution) |
10,105,444 |
Valeant Pharms. North America LLC v. Mylan Pharms. Inc., 19-8233 (D.N.J.) |
Mar. 8, 2019 |
Hon. Peter G. Sheridan |
Jublia® (efinaconazole topical solution) |
10,105,444 |
Valeant Pharms. North America LLC v. Mylan Pharms. Inc., 19-0037 (N.D.W.V.) |
Mar. 11, 2019 |
Hon. Thomas S. Kleeh |
Jublia® (efinaconazole topical solution) |
10,105,444 |
Pfizer Inc. v. Ajanta Pharma Ltd., 19-0517 (D. Del.) |
Mar. 15, 2019 |
Hon. Leonard P. Stark |
Xeljanz® (tofacitinib tablets) |
6,965,027
RE41,783 |
Biodelivery Sciences Int’l, Inc. v. Chemo Research, S.L., 19-8660 (D.N.J.) |
Mar. 15, 2019 |
Hon. Kevin McNulty |
Belbuca® (buprenorphine buccal film) |
8,147,866
9,655,843
9,901,539 |
Keryx Biopharmaceuticals, Inc. v. Mylan Pharms. Inc., 19-0040 (N.D.W.V.) |
Mar. 15, 2019 |
Hon. Thomas S. Kleeh |
Auryxia® (ferric citrate tablets) |
5,753,706
7,767,851
8,093,423
8,299,298
8,338,642
8,609,896
8,754,257
8,754,258
8,846,976
8,901,349
9,050,316
9,328,133
9,387,191
9,757,416 |
Celgene Corp. v. Teva Pharms. USA, Inc., 19-8758 (D.N.J.) |
Mar. 19, 2019 |
Hon. Esther Salas |
Pomalyst® (pomalidomide capsules) |
10,093,647
10,093,648
10,093,649 |
Mayne Pharma Int’l Pty Ltd. v. Prinston Pharm. Inc., 19-0549 (D. Del.) |
Mar. 21, 2019 |
Hon. Richard G. Andrews |
Doryx® MPC (doxycycline hyclate delayed-release tablets) |
9,295,652
9,446,057
9,511,031 |
Sandoz Inc. v. Pharmacyclics LLC, IPR2019-00865 (PTAB) |
Mar. 21, 2019 |
N/A |
Imbruvica® (ibrutinib tablets)
Imbruvica® (ibrutinib capsules) |
9,795,604 |
Mallinckrodt Hospital Products IP Ltd. v. Altan Pharma Ltd., 19-0552 (D. Del.) |
Mar. 22, 2019 |
Hon. Leonard P. Stark |
Ofirmev® (acetaminophen for injection) |
9,399,012
9,610,265
9,987,238
6,992,218 |
Vanda Pharms. Inc. v. Teva Pharms. USA, Inc., 19-0560 (D. Del.) |
Mar. 22, 2019 |
Hon. Colm F. Connolly |
Hetlioz® (tasimelteon capsules) |
10,149,829 |
Indivior Inc. v. Aveva Drug Delivery Systems, Inc., 19-60757 (S.D. Fla.) |
Mar. 22, 2019 |
Hon. Beth Bloom |
Suboxone® (buprenorphine HCl / naloxone HCl sublingual film) |
8,017,150
8,603,514
9,687,454
9,931,305 |
Boehringer Ingelheim Pharma GmbH & Co. KG v. Aurobindo Pharma Ltd., 19-8840 (D.N.J.) |
Mar. 22, 2019 |
Hon. Brian R. Martinotti |
Pradaxa® (dabigatran etexilate mesylate capsules) |
6,087,380 |
Eli Lilly and Co. v. Dr. Reddy’s Labs., Ltd., 19-1246 (S.D. Ind.) |
Mar. 27, 2019 |
Hon. Jane Magnus-Stinson |
Alimta® (pemetrexed for injection) |
7,772,209 |
Eagle Pharms., Inc. v. Accord Healthcare, Inc., 19-0344 (M.D.N.C.) |
Mar. 27, 2019 |
Hon. William L. Osteen, Jr. |
Argatroban Injections |
7,589,106
7,687,516 |
Eagle Pharms., Inc. v. Accord Healthcare, Inc., 19-9031 (D.N.J.) |
Mar. 27, 2019 |
Hon. Claire C. Cecchi |
Argatroban Injections |
7,589,106
7,687,516 |